کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2404100 | 1102952 | 2010 | 9 صفحه PDF | دانلود رایگان |
This randomized double-blind study aimed to determine the safety and immunogenicity of a gp120/NefTat candidate human immunodeficiency virus type 1 (HIV-1) vaccine formulated with one of three different Adjuvant Systems (AS02A, AS02V and AS01B) in healthy HIV-seronegative adults. All vaccine formulations induced strong HIV-specific CD4+ T-cell responses characterized by high lymphoproliferative capacity and IL-2 production that were still detectable 18 months after last immunization, with strongest responses seen in the AS01B group. Broad coverage was demonstrated against gp120, and to a lesser extent Nef, derived from the most common circulating clades (B, C and circulating recombinant form [CRF]-01). All vaccine formulations exhibited acceptable safety and reactogenicity profiles. The demonstration of superior CD4+ T-cell induction by AS01B provides important guidance for future HIV vaccine development.
Journal: Vaccine - Volume 28, Issue 43, 8 October 2010, Pages 7016–7024